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CASE REPORT
Pediatric spinal glioblastoma of the 
conus medullaris: a case report of long survival
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Abstract 
High‑grade gliomas of the spinal cord represent a rare entity in children. Their biology, behavior, and controversial 
treatment options have been discussed in a few pediatric cases. These tumors are associated with severe disability 
and poor prognosis. We report a case of a 4‑year‑old child diagnosed with an isolated glioblastoma multiforme of the 
conus medullaris. The patient underwent subtotal surgical excision, followed by adjuvant radiotherapy and oral chem‑
otherapy. He is alive with mild neurologic deficits at 52 months after diagnosis. We describe the peculiar characteris‑
tics of this rare condition in pediatric oncology. We also provide an overview of current multidisciplinary therapeutic 
approaches and prognostic factors for this disease.
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Background
Primary spinal cord tumors are rare in children and 
account for less than 1% of all central nervous system 
(CNS) cancers [1]. In adults, spinal neoplastic lesions are 
mostly represented by extramedullary tumors (almost 
80% of cases), whereas the rate of intramedullary tumors 
in children reaches up to 35% of all spinal neoplasms [2].
Low-grade astrocytomas represent the most frequently 
found histological type of intramedullary lesion (50%–
88% of cases), approximately 1%–3% are high-grade 
gliomas, whereas non-glial tumors are less common [3]. 
Spinal glioblastoma multiforme (GBM) is a highly malig-
nant CNS tumor that is clinically, histologically, and 
genetically heterogeneous. Spinal GBM is only rarely 
seen in children and represents 1%–5% of all GBMs [1].
In this paper, we report a rare case of spinal GBM of 
the conus medullaris that occurred in a 4-year-old child. 
We further describe the peculiar characteristics of this 
rare entity in childhood and illustrate the current multi-
disciplinary therapeutic approaches.
Case presentation
A 4-year-old boy reported a 6-month history of night-
time worsening pain of both of the lower limbs and a sub-
sequent appearance of urinary retention and weight loss. 
Neurologic examination demonstrated right leg paresis 
with bilateral hyporeflexia of the lower limbs. There were 
no neurologic abnormalities of the upper limbs and cra-
nial nerves. No saddle anesthesia was observed.
Brain and spine magnetic resonance imaging (MRI) 
revealed a large heterogeneous ovoid mass of 8 cm in the 
major diameter that filled the spinal canal between T11 
and L3 (Fig. 1a, b) with inhomogeneous enhancement of 
the tumor area (Fig. 1c). A perilesional hemorrhagic area 
was observed (Fig.  1d). No other lesions were observed 
by brain or spinal MRI.
Microsurgical subtotal excision was performed with 
intraoperative neurophysiologic monitoring. After open-
ing the dura, a brownish-red, highly vascularized solid 
mass appeared. At the end of the procedure, the excision 
appeared to be subtotal, as confirmed by postoperative 
MRI (Fig.  2a, b). The patient’s clinical status worsened 
after surgery, with worse paraparesis on the right side. 
Hypoesthesia with a D11 level and urinary incontinence 
were also observed. Pathology was suggestive of GBM 
(Fig. 3).
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Mutational analyses for tumor protein 53 (TP53), lysine 
27 on histone H3 (H3K27), and isocitrate dehydrogenase 
1 (IDH1) genes were performed, but no overexpression 
or mutations were identified.
The child underwent focal radiotherapy of the conus 
medullaris lesion (a dose of 4500  cGy delivered in 25 
fractions) with temozolomide (TMZ, with a daily dose 
of 75 mg/m2 during irradiation; a daily dose of 150 mg/
m2 for 5  days, with a 3-week interval for the first cycle 
after irradiation; a daily dose of 200  mg/m2 for 5  days, 
repeated every 28  days for the following 11 cycles) [4]. 
No severe adverse effects related to adjuvant treatment 
were observed and, in particular, there was no delay in 
treatment because of hematologic toxicities.
The patient underwent neuro-rehabilitation with a 
gradual improvement of his motor weakness. He was 
soon able to stand and walk with a walking device. 
At 52  months after surgery, his motor impairment 
was almost completely resolved, although the patient 
continued to have a mild urinary retention syndrome. 
Late follow-up imaging confirmed complete remission in 
this patient (Fig. 2c, d).
Discussion
Pediatric intramedullary GBM are uncommon clinical 
entities. The commonly reported locations of GBM are 
the cervicothoracic segments, with the cervical spine 
being the most affected region, followed by the tho-
racic spine [5]. The isolated involvement of the conus 
medullaris is very infrequent, representing only 3  % of 
all pediatric cases, whereas holocordal presentations 
and intracranial dissemination are often described. The 
tumor typically tends to spread via the subarachnoid 
space due to the proximity of the neoplastic tissue to 
the cerebrospinal fluid space. Survival ranges from 4 to 
16 months with a median survival of 12 months [6].
Clinical features depend on the region of the spi-
nal cord involved and the growth rate of the tumor, 
Fig. 1 Magnetic resonance imaging (MRI) of a 4‑year‑old boy with spinal glioblastoma multiforme (GBM) of the conus medullaris at the time of 
diagnosis. MRI shows a large heterogeneous mass extensively filling the spinal canal between T11 and L3. The lesion shows hyperintense and inho‑
mogeneous signal intensity on Sagittal T2‑weighted images (a) and isointense signal intensity on Sagittal T1‑weighted images (b). After gadolinium 
(Gd) injection, a diffuse, inhomogeneous enhancement of the tumor is observed, and the tecal sac is filled by abundant enhancing tissue envelop‑
ing the conus medullaris and cauda equina (c). The regions of hypointensity within the tumor and along the inferior margin of the lesion shown on 
sagittal T2‑weighted images suggest tumoral bleeding (arrow) (d)
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irrespective of the histological subtype. The most com-
mon symptoms in children include pain, motor regres-
sion, gait abnormalities, torticollis, and progressive 
kyphoscoliosis.
Based on imaging, the criteria for the differential diag-
nosis of these lesions in children have been determined 
[7]. Our case showed MRI features compatible with a 
high-grade neoplasm, including hemorrhage involving 
the lower pole, the so-called “cap sign,” the presence of 
multiple cysts, and leptomeningeal involvement [7].
Similar to the treatment strategy for brain lesions, gross 
total resection of the spinal cord lesion, confirmed by 
early postoperative MRI, followed by adjuvant treatment 
consisting of radiotherapy and chemotherapy, has been 
recommended [7].
Historically, pediatric GBM has been treated with adju-
vant radiotherapy followed by cytotoxic drugs either as 
single agents or in combination. Unfortunately, none of 
the chemotherapeutic regimens has been demonstrated 
to be superior over the others [8].
Due to the lack of alternative treatments with superior 
clinical efficacy, radiotherapy in combination with con-
comitant and adjuvant TMZ is widely used by pediatric 
neuro-oncologists based on the efficacy of this strategy in 
adults [9]. This treatment regimen is also used in patients 
with spinal GBM.
Because of the high propensity of spinal GBM to dis-
seminate, whole spine irradiation has been proposed. 
However, the role of prophylactic craniospinal irradiation 
remains unclear [10]. Taking the patient’s age and mini-
mal residual disease into consideration, we decided to 
perform focal irradiation at the 52-month follow-up visit 
when there was no evidence of dissemination.
Pediatric GBM usually has a grim prognosis. Survival 
ranges from 6 to 16  months, with a mean survival of 
12 months after the diagnosis [1]. An exceptionally long 
survival of 144  months has been reported for a patient 
with spinal GBM [11].
The extent and location of the lesion as well as the fea-
sibility of a gross total resection, especially in younger 
patients, are the factors that most affect a patient’s prog-
nosis [12]. Despite the presence of several positive prog-
nostic factors, survival remains poor [13].
Even after 52 months of follow-up, our patient is not con-
sidered to be cured. Intensive rehabilitation aiming at opti-
mal clinical recovery has promoted a good quality of life and 
the ability to perform daily life activities without support.
The good clinical outcome observed in our case might 
partially be due to the absence of known negative prog-
nostic molecular markers described in pediatric high-
grade gliomas such as TP53 and H3K27 [14, 15]. The 
identification of new molecular markers helps to define 
the prognosis of GBM in daily practice [16].
Fig. 2 Postoperative MRI of the boy with spinal GBM of the conus 
medullaris. Postoperative MRI shows a subtotal resection of the 
primary lesion and leptomeningeal involvement at the level of the 
conus medullaris and cauda equine (arrows) (a); after Gd injection, 
there is no contrast enhancement (arrows) (b). Two years after sur‑
gery, MRI shows the absence of relapses (c) and stable persistence of 
the previously documented enhancement along the right anterolat‑
eral conus medullaris (level D10‑D12) and along the cauda equina (d)
Page 4 of 4Cacchione et al. Chin J Cancer  (2016) 35:44 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Authors’ contributions
AC and AM wrote the first draft and revised the manuscript. MGC, MR and 
AB cared for the patients. GSC and FD selected the neuro‑images, made 
the figures, and drafted legends. AC has been crucial in designing the work 
and supervising the draft revision. All authors read and approved the final 
manuscript.
Author details
1 Department of Pediatric Hematology‑Oncology, Bambino Gesù Children’s 
Hospital, IRCCS, Piazza Sant’Onofrio 4, 00165 Rome, Italy. 2 Neuroradiology 
Unit, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, 
Italy. 3 Division of Pathology, Bambino Gesù Children’s Hospital, Piazza 
Sant’Onofrio 4, 00165 Rome, Italy. 4 Department of Neurosurgery, Fondazione 
Istituto Neurologico “Carlo Besta”, IRCCS, Milan, Italy. 5 Neurosurgery Unit, 
Department of Neuroscience and Neurorehabilitation, Bambino Gesù Chil‑
dren’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, Italy. 
Acknowledgements
We are grateful to Prof. Franco Locatelli for his substantial contribution to con‑
ception, critical supervision, and clinical support in realizing this manuscript.
Competing interests
We have not financial competing interests to declare. In relation to the manu‑
script, we do not have political, personal, religious, ideological, academic, 
intellectual, commercial competing interests to declare.
Received: 28 September 2015   Accepted: 1 March 2016
References
 1. Mori K, Imai S, Shimizu J, Taga T, Ishida M, Matsusue Y. Spinal glioblastoma 
multiforme of the conus medullaris with holocordal and intracranial 
spread in a child: a case report and review of the literature. Spine J. 
2012;12(1):e1–6.
 2. Winograd E, Pencovich N, Yalon M, Soffer D, Beni‑Adani L, Constantini S. 
Malignant transformation in pediatric spinal intramedullary tumors: case‑
based update. Childs Nerv Syst. 2012;28(10):1679–86.
 3. Fakhreddine MH, Mahajan A, Penas‑Prado M, Weinberg J, McCutcheon IE, 
Puduvalli V, et al. Treatment, prognostic factors, and outcomes in spinal 
cord astrocytomas. Neuro Oncol. 2013;15(4):406–12.
 4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, 
et al. Effects of radiotherapy with concomitant and adjuvant temozo‑
lomide versus radiotherapy alone on survival in glioblastoma in a ran‑
domised phase III study: 5‑year analysis of the EORTC‑NCIC trial. Lancet 
Oncol. 2009;10(5):459–66.
 5. Pollack IF. Intramedullary spinal cord astrocytomas in children. Pediatr 
Blood Cancer. 2004;43:617–8.
 6. Medhkour A, Chan M. Extremely rare glioblastoma multiforme of the 
conus medullaris with holocord and brain stem metastases, leading to 
cranial nerve deficit and respiratory failure: a case report and review of 
the literature. Surg Neurol. 2005;63:576–82.
 7. Mechtler LL, Nandigam K. Spinal cord tumors: new views and future 
directions. Neurol Clin. 2013;31(1):241–68.
 8. Vanan MI, Eisenstat DD. Management of high‑grade gliomas in 
the pediatric patient: past, present, and future. Neurooncol Pract. 
2014;1(4):145–57.
 9. Fangusaro J, Warren KE. Unclear standard of care for pediatric high grade 
glioma patients. J Neurooncol. 2013;113(2):341–2.
 10. Konar SK, Maiti TK, Bir SC, Kalakoti P, Bollam P, Nanda A. Predictive factors 
determining the overall outcome of primary spinal glioblastoma multi‑
forme: an integrative survival analysis. World Neurosurg. 2016;86:341–8.
 11. Viljoen S, Hitchon PW, Ahmed R, Kirby PA. Cordectomy for intramedullary 
spinal cord glioblastoma with a 12 year survival. Surg Neurol Int. 2014;5:101.
 12. Ononiwu C, Mehta V, Bettegowda C, Jallo G. Pediatric spinal glioblastoma 
multiforme: current treatment strategies and possible predictors of 
survival. Childs Nerv Syst. 2012;28(5):715–20.
 13. Derinkuyu BE, Boyunaga O, Okur A, Alimli AG, Oztunali C, Damar C, 
et al. Primary intraspinal glioblastoma multiforme in a child. Spine J. 
2015;15(12):e37–8.
 14. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, 
et al. Prognostic significance of histological grading, p53 status, YKL‑40 
expression, and IDH1 mutations in pediatric high‑grade gliomas. J Neu‑
rooncol. 2010;99(2):209–15.
 15. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The 
histone H3.3K27M mutation in pediatric glioma reprograms H3K27 meth‑
ylation and gene expression. Genes Dev. 2013;27(9):985–90.
 16. Hofer S, Rushing E, Preusser M, Marosi C. Molecular biology of high‑grade 
gliomas: what should the clinician know? Chin J Cancer. 2014;33(1):4–7.
Fig. 3 Histopatologic features of the spinal GBM of the conus medullaris. Microscopy demonstrates a neoplastic proliferation of polymorphous 
glial cells characterized by anisocaryosis and atypical mitosis. a Focal necrosis, calcifications, and areas with multinucleated cells are present (×40). 
b Immunohistochemistry shows positivity for glial fibrillary acidic protein (GFAP) and S100 and negativity for sinaptofisine, neurofilaments, and the 
epithelial membrane antigen (EMA) (×63). c The proliferation index (anti‑Ki67) is 15% (×63)
